Pay in 4 interest-free payments of $6.52 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
In recent years, IDH inhibitors targeting IDH mutants, including ivosidenib and enasidenib (Table 1), have been approved by the Food and Drug Administration to be used in patients with IDH1 or IDH2 mutant recurrent or refractory AML, respectively (Kim, 2017
Lifestyle factors like smoking, alcohol consumption, stress, and poor diet can reduce glutathione levels in the body, thereby affecting the longevity of the treatment effects
This medication may cause low potassium levels in the blood (hypokalemia)
Certain characteristics of lymphadenopathy warrant prompt or urgent medical attention
US$ 24.86
US$ 25.52
US$ 29.20
US$ 28.88
US$ 28.30
US$ 26.67
